WuXi TIDES投产全新多肽生产线及大规模连续流纯化系统

合全药业 2023-04-09

2023年4月6日，药明康德子公司合全药业宣布在常州基地，投产两个2,000升多肽固相合成釜以及大规模连续流纯化设备，进一步提升了WuXi TIDES平台的能力和产能。作为合全药业的重要组成部分，WuXi TIDES是端到端CRDMO平台，能够为寡核苷酸、多肽及相关化学偶联药物，提供覆盖药物发现、CMC研究及生产的一站式服务。

合全药业常州基地

随着两个2,000升多肽固相合成釜的启用，WuXi TIDES多肽固相合成釜总体积已超过10,000升。除了多肽产能的大幅提升，WuXi TIDES还新增连续流纯化系统，配备了300-DAC双柱系统，适用于公斤级多肽和寡核苷酸类产品的连续纯化。使用连续纯化模式可缩短纯化周期，降低溶剂消耗，使得多肽和寡核苷酸的生产变得更加高效、绿色环保。

药明康德联席首席执行官、合全药业首席执行官陈民章博士表示：“未来我们将继续提升WuXi TIDES CRDMO平台的能力和产能，加速寡核苷酸、多肽及多种新型偶联药物的开发进程，解决未满足的临床需求，造福全球病患。”

关于合全药业

合全药业是药明康德子公司，在亚洲、北美及欧洲地区均设有研发及生产基地。合全药业服务于生命科学行业，拥有卓越的化学创新药研发和生产的能力和技术平台。作为全球新药合同研究、开发与生产领域（CRDMO）的领军企业，合全药业致力于为全球合作伙伴提供高效、灵活、高质量的一站式解决方案，以支持包括小分子、寡核苷酸、多肽及各种复杂化学偶联药物的研发与生产。更多信息，请访问公司网站：www.stapharma.com.cn

WuXi TIDES Adds New Peptide Manufacturing Capacity and Large-Scale Continuous Purification System

Expansion Enhances WuXi TIDES CRDMO Platform Capability and Capacity for Global Partners

April 6, 2023 - WuXi STA, a global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has added two 2,000 L reactors and a large-scale continuous purification system for peptide manufacturing at the Changzhou campus. The new additions further enhance the capability and capacity of WuXi TIDES. As an integral part of WuXi STA, WuXi TIDES is an end-to-end CRDMO platform for oligonucleotide, peptide, and related synthetic conjugates (“TIDES” drugs), simplifying the TIDES drug development by providing all discovery, CMC development, and the entire manufacturing supply chain under one roof.

With the two new 2,000 L reactors in operation, the total reactor volume of the Solid Phase Peptide Synthesizers (SPPS) at WuXi TIDES has increased to over 10,000 L.

Besides significant peptide capacity expansion, WuXi TIDES also added a new continuous purification system that features 300-DAC twin columns for continuous purification of kilogram-scale peptide and oligonucleotide. The continuous mode enables a purification process with a faster turnaround time and lower solvent consumption, allowing for a more efficient and sustainable peptide and oligonucleotide manufacturing.

Dr. Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA, said, "We are pleased to support our global partners in their efforts to develop TIDES therapies for patients in need. We are committed to continuously enhancing our WuXi TIDES CRDMO platform's capacity and capability to expedite the development and commercialization of more innovative therapies for patients worldwide."

About WuXi STA

WuXi STA (stapharma.com), a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations across Asia, North America, and Europe. As a premier Contract Research, Development, and Manufacturing Organization (CRDMO), WuXi STA offers its worldwide partners efficient, flexible and high-quality solutions for integrated chemical, manufacturing and controls (CMC) from preclinical to commercial uses, including the development and manufacturing of small molecule, oligonucleotide, peptide and various complex chemical conjugate. For more information, please visit: http://www.STApharma.com

内容来源：合全药业药明康德
责任编辑：胡静审核人：何发

WuXi TIDES投产全新多肽生产线及大规模连续流纯化系统

评论

热点文章